Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce The Final Results For Its BRIDGE Phase 3 Open-Label Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics and Chiesi Global Rare Diseases have announced the final results of their BRIDGE Phase 3 clinical trial. The trial evaluated Pegunigalsidase Alfa for treating Fabry Disease, showing positive outcomes.
December 30, 2020 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protalix BioTherapeutics announced positive final results from its BRIDGE Phase 3 trial for Pegunigalsidase Alfa, a treatment for Fabry Disease. This could boost investor confidence and impact stock prices positively.
The positive results from the Phase 3 trial are significant for Protalix as they demonstrate the efficacy of Pegunigalsidase Alfa, potentially leading to regulatory approval and increased market confidence. This is likely to have a positive impact on PLX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90